Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients.
Fiche du document
6 mai 2019
- doi: 10.1084/jem.20181618
- issn: 0022-1007
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1084/jem.20181618
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/30975896
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1540-9538
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_83C31BFEAA5C1
info:eu-repo/semantics/openAccess , CC BY-NC-SA 4.0 , https://creativecommons.org/licenses/by-nc-sa/4.0/
Sujets proches
Integument (Skin) Cutis Factors Agents, Manufacturers' Manufacturers' representatives Factors Biologic markers Biological markers Biomarkers Markers, BiochemicalCiter ce document
MAS Broggi et al., « Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients. », Serveur académique Lausannois, ID : 10.1084/jem.20181618
Métriques
Partage / Export
Résumé
Liquid biopsies allow monitoring of cancer progression and detection of relapse, but reliable biomarkers in melanoma are lacking. Because secreted factors preferentially drain to lymphatic vessels before dilution in the blood, we hypothesized that lymph should be vastly enriched in cancer biomarkers. We characterized postoperative lymphatic exudate and plasma of metastatic melanoma patients after lymphadenectomy and found a dramatic enrichment in lymphatic exudate of tumor-derived factors and especially extracellular vesicles containing melanoma-associated proteins and miRNAs, with unique protein signatures reflecting early versus advanced metastatic spread. Furthermore, lymphatic exudate was enriched in memory T cells, including tumor-reactive CD137 + and stem cell-like types. In mice, lymph vessels were the major route of extracellular vesicle transport from tumors to the systemic circulation. We suggest that lymphatic exudate provides a rich source of tumor-derived factors for enabling the discovery of novel biomarkers that may reflect disease stage and therapeutic response.